The company said, “We reiterate full year 2024 guidance for Oncology/Immunology consolidated revenue is $300 million to $400 million, driven by 30% to 50% growth target in oncology marketed product revenue. HUTCHMED’s work in 2024 and beyond will be supported by its strong balance sheet. The Company is thus well placed to deliver against its target to become a self-sustaining business and its goal to bring its innovative medicines to patients globally through its own sales network in China markets and through partners worldwide.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- HUTCHMED’s Cancer Drug Fast-Tracked in China
- HUTCHMED to Announce 2024 Half-Year Financial Results
- Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
- HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology